Oxybutynin: short-term supply of tablets and discontinuation of oral liquid

The oral liquid is being discontinued. A small supply of tablets has been sourced. All presentations are restricted to existing patients only.

On this page

Why are we doing this?

Oxybutynin, 5 mg tablets and oral liquid 5 mg per 5 ml were supplied by Apotex. Apotex has left the New Zealand market.

We have had difficulty sourcing an alternative supplier for oxybutynin.

We are making these changes so existing patients can access oxybutynin for as long as possible. We acknowledge the inconvenience this may cause to patients, pharmacists and prescribers.

Oxybutynin tab 5 mg: new supply

From 1 June 2021, we restricted funding to people who were using oxybutynin before 1 June 2021.

Pharmacists can endorse the script where they have a record of a previous dispensing of oxybutynin.

New listing of 1 year's supply

We secured a year’s supply of oxybutynin tablets from Alchemy Health.

The new brand, Oxybutynin Stada, is funded from 1 January 2022.

Oxybutynin Stada is not Medsafe-approved. As such it needs to be prescribed and supplied to patients under Section 29 of the Medicines Act.

Prescribing and supplying a medicine under section 29

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors. 

We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no oxybutynin tablets. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)

Oxybutynin oral liq 5 mg per 5 ml: discontinued

We could not find an alternative supplier of the oral liquid presentation of oxybutynin (pharmacode 340413).

On 1 June 2021, we restricted funding to people who were using oxybutynin before 1 June 2021.

The product was delisted on 1 May 2022. We anticipated that supplies of oxybutynin oral liquid ran out before being delisted.

People using the oral liquid will need to be changed to an alternative product.

Alternative product: Solifenacin

We have received clinical advice that solifenacin is a suitable funded alternative for most patients. Both 5 mg and 10 mg tablets of solifenacin are fully subsidised.

Schedule listing for solifenacin(external link)

Solifenacin in the NZ Formulary(external link)

Who to contact

If you are taking oxybutynin, talk to your pharmacist or the person who prescribed the oxybutynin. They are in the best place to advise on your clinical circumstances. 

Read more about the Apotex changes(external link) 

If you have funding questions about oxybutynin, email enquiry@pharmac.gov.nz